Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Elastic NV (ESTC) Price & Performance

ADMA Biologics IncTrade
Elastic NVTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Elastic NV — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Elastic NV trades at $76.44 (market cap $7.93B). The key difference: Elastic NV is far larger — about 3.6× ADMA Biologics Inc's market cap, and Elastic NV is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMAESTC
Market Cap
$2.18B$7.93B
Sector
HealthTechnology
52-Week High
$20.38$94.47
52-Week Low
$7.60$43.30
Enterprise Value
$2.25B$7.15B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Elastic NV

Elastic N.V. (ESTC) trades at $75.11, up 7.38% in the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent earnings beats, including Q1 2026 EPS of $0.61 versus $0.561 expected, highlight operational strength. The company announced AI collaborations with OpenAI and AWS security distinctions, driving positive sentiment.

Outlook remains positive due to growth prospects in AI and security, but risks include high valuation multiples and ongoing legal investigations. The stock offers upside to the consensus price target of $74.21, though investors should weigh profitability improvements against competitive pressures.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC